Non-invasive Alzheimer’s Disease Diagnostic Kit


In every 3 seconds, there is one person diagnosed with Alzheimer’s Disease (AD) as reported by the World Health Organisation. As the ageing population is expanding, dementia has become a tremendous socioeconomic issue. Nowadays, there are over 33 million of people having AD that is accounted for 0.4% of the world population. Unfortunately, there is no cure for AD, only early diagnosis and treatment can ameliorate the symptoms and delay its progression.

Several biomarkers in cerebrospinal fluid (CSF) have been recognized and established for AD diagnosis with high diagnostic accuracy over 85%. However, the collection of CSF is invasive and causes discomfort and side effect on patients. On the other hand, the collection of urine and saliva is relatively simple and non-invasive.

Our technology provides a solution for early Alzheimer’s disease diagnosis by using magnetic nanoprobe for sensitive detection of the target biomarker in different body fluids including blood serum, saliva and urine. In addition, our detection assay has a wide dynamic range that allows the quantification of biomarkers in a minute amount (a few microliters) of samples. It is proven practically useful for different body fluids. It is a non-invasive, rapid and cost-effective alternative for accurate diagnosis of AD.



Our detection assay is an immunocomplex based approach with magnetic nanoprobe for sensitive detection of the target biomarker in different body fluids including blood serum, saliva and urine. Once the target biomarker is captured, a sandwich immunocomposite will be formed. The immunocomposite will then be labelled by our tailor-made fluorophore which gives amplified fluorescence signal for quantification. 

When comparing to commercially available ELISA kits, our new diagnostic kit provides additional options on the sample types and allows testing on saliva and urine. Furthermore, our assay is 100x more sensitive than the commercially available ELISA kit. The limit of detection (LOD) is down to Femto (10E-15) molar regime (0.104 pg/mL), that means the concentration requirement of AD biomarkers being detected for the new kit is much lower than the cut-off for those ELISA kits.

Besides, our new kit takes only 1.5 hrs to obtain result while the ELISA kit may generally take 18 hrs for that. For a typical analysis, speed is one of the merits. It saves running cost. Short time allows future point of care products more feasible. Last but not least, the cost of the new kit is about 100 USD, which is 50 times cheaper than the ELISA kit.


Key features:

  • Non-invasive
  • Ultra-sensitive (100x more sensitive than commercially available ELISA kit)
  • Cost-effective, simple and direct AD early detection and diagnostics
  • Low sample consumption (a few µL)



With our novel nanoparticle-based technology, a diagnosis kit is developed for:

  • High-throughput detection of Alzheimer's Disease biomarkers
  • Non-invasive point-of-care diagnosis of Alzheimer's Disease


Besides, two different diagnostic approaches will be further developed:

  1. A non-invasive and user-friendly magnetic nanoparticle platform for direct quantification of circulating biomarkers in body fluids.
  2. A novel biomarker specific MRI contrast agent for in-vivo imaging of the disease-associated protein plaque in the brain.

These diagnostic tools could provide a practical platform for population-wide screening for neurodegenerative diseases.



There are over 55 million people worldwide living with dementia in 2020 and this number is estimated to reach 78 million in 2030 and 139 million in 2050. Alzheimer's Disease is the most common form of dementia and may contribute to 60-70% of cases.

The Alzheimer's Disease diagnostics and therapeutics market was valued at USD 6,632.82 million in 2020, and it is estimated to reach approximately USD 9,073 million in 2026 at a CAGR of 5.36%.



  • Early detection and diagnostic for neurodegenerative diseases, which is cost-effective, simple and quick
  • Measure the subtle changes in the expression profile of disease-associated biomarkers


Chemical - Bio-based
Healthcare - Diagnostics
Life Sciences - Biotech Research Reagents & Tools
Technology Status

Licensed but Available

Technology Readiness Level

Alzheimer's Disease, Diagnostic, Non-invasive, Biomarker, Nanoprobe, Fluorophore

Published on
Feb 11, 2021
Updated on
Mar 24, 2021
Make an Enquiry